Rezolute, Inc. - 8-K Filing
FDA recommends a pre-BLA meeting for ersodetug in congenital HI following sunRIZE trial data review (Items: 7.01 Regulation FD Disclosure)
Tickers: $RZLT
FDA recommends a pre-BLA meeting for ersodetug in congenital HI following sunRIZE trial data review (Items: 7.01 Regulation FD Disclosure)
Tickers: $RZLT